CBUS

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, Farmer, Gene editing, Entrepreneurship, HT1, Seed, HT2, Net, Bayer, PSR, Breeding, CBUS, WOSR, European Parliament, Agriculture

We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.

Key Points: 
  • We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.
  • This vote was a significant milestone for our entire industry and is a crucial step that will help Cibus usher in the gene editing era."
  • 2 Cibus Powered™ is the internal Cibus trait standard that ensures each Cibus trait meets minimum efficacy and quality assurance commercial requirements.
  • Cibus will host a live webcast, Thursday, March 21, 2024, at 4:30 p.m. Eastern Standard Time to discuss its fourth quarter 2023 financial results and provide a business update.

Cibus Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Editorial, Culture, Organization, Regeneration, Entrepreneurship, MIC, Agriculture, SAN, HT1, AI, Hope, Seed, HT2, ITunes, PSR, Most, CBUS, Heart, Breeding, Food, Gene editing

Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.

Key Points: 
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • “We are extremely proud to be recognized by Fast Company as one of the world’s most innovative companies of 2024,” stated Rory Riggs, Co-Founder, Chairman, and CEO of Cibus.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.

Cibus to Participate in the 36th Annual Roth Conference

Retrieved on: 
Wednesday, March 13, 2024
Seed, Transition, SAN, Conference, Entrepreneurship, CBUS

SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer will participate in a panel at the 36th Annual Roth Conference taking place March 17-19, 2024.

Key Points: 
  • SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer will participate in a panel at the 36th Annual Roth Conference taking place March 17-19, 2024.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call

Retrieved on: 
Thursday, March 7, 2024
Seed, International, SAN, Transition, CBUS, News

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2023 financial results on Thursday, March 21, 2024.

Key Points: 
  • SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2023 financial results on Thursday, March 21, 2024.
  • Cibus’ management team will host a conference call and audio webcast at 4:30 p.m.
  • ET on that day to discuss the financial results and other company updates.
  • An archived webcast will be available on the Company's website for 90 days after the event.

Cibus and Loveland Products Collaborate to Develop and Sell Rice Traits in the US

Retrieved on: 
Monday, February 26, 2024
Weed control, SAN, Senior, CBUS, TSX, Transition, Nutrien, Genetics, NTR, Agriculture

Cibus has agreed to collaborate with Loveland Products to provide traits into Loveland’s elite rice seed genetics.

Key Points: 
  • Cibus has agreed to collaborate with Loveland Products to provide traits into Loveland’s elite rice seed genetics.
  • “Loveland Products is constantly striving to bring innovative solutions to the marketplace across the agricultural industry,” says Rob Dunlop, Vice President of North America seed at Nutrien.
  • “We are excited to collaborate with Cibus to help address some of the most pressing weed management challenges of US rice growers.”
    “We are thrilled to work with the Loveland Products and Dyna-Gro teams to deliver new herbicide management options to rice growers,” stated Norm Sissons, Senior Vice President Commercial at Cibus.
  • “Importantly, our recent results using our Trait MachineTM to add traits like herbicide tolerance in rice show we can provide collaborators with new traits in their elite genetics on an accelerated timescale.”

European Parliament Votes to Support Proposal for the Regulation of New Genomic Techniques

Retrieved on: 
Wednesday, February 7, 2024
Nature, Policy, Plant, CBUS, SAN, Civil service commission, Senior, NGT, Legislation, Agriculture, Gene editing, NASA Exoplanet Archive, Environment, European, Food, Government, Climate, Pesticide, European Commission, European Parliament, EU Council, International development, Disease, Natural Resources, Farmer, Eus, European Council, MEP, Breeding, Parliament

The European Parliament completes a landmark vote in favour of the European Commission proposal to introduce a new regulation for plants obtained by certain new genomic techniques (NGTs) and their food and feed.

Key Points: 
  • The European Parliament completes a landmark vote in favour of the European Commission proposal to introduce a new regulation for plants obtained by certain new genomic techniques (NGTs) and their food and feed.
  • Cibus applauds the EU Parliament supporting a science-based approach developed following many years of discussion and engagement with stakeholders and expert groups.
  • The EU Parliament met 5-8 February in Strasbourg and, following a debate on Tuesday Feb 6th, the Parliament voted in favour of the NGT legislation the following day.
  • MEP and rapporteur Jessica Polfjärd said of the vote, “Historic step forward: the European Parliament supports my proposal for sustainable use of new genomic techniques (NGT).

European Parliament’s Environment Committee Votes to Support New Proposal for the Regulation of New Genomic Techniques

Retrieved on: 
Thursday, January 25, 2024
Senior, MEP, European Parliament, Food safety, Legislation, NGT, Government, Food, Natural Resources, Breeding, Policy, SAN, Agriculture, Food security, Civil service commission, European, European Commission, Transition, International development, NASA Exoplanet Archive, Parliament, CBUS, Plant, Council, Nature

The Environment Committee of the European Parliament votes in favour of the European Commission proposal to introduce a new regulation on plants obtained by certain new genomic techniques (NGTs) and their food and feed.

Key Points: 
  • The Environment Committee of the European Parliament votes in favour of the European Commission proposal to introduce a new regulation on plants obtained by certain new genomic techniques (NGTs) and their food and feed.
  • The Committee’s report indicates that NGTs have the ability to enhance agriculture by making crops more resilient and sustainable whilst providing unprecedented opportunities for European agriculture and food production.
  • The legislation is part of a package of EU proposals to ensure resilient and sustainable use of the EU's natural resources.
  • After the vote, MEP and rapporteur Jessica Polfjärd said, “This proposal is critical for strengthening Europe's food safety in a sustainable manner.

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Retrieved on: 
Wednesday, January 17, 2024
Senior, Research, SAN, New product development, Genetics, University, PSR, Weed control, Rapeseed, CBUS, WOSR, Gene editing, HT1, Agriculture

2023 field trial results have confirmed that rice herbicide tolerance (HT) traits, known as HT1 and HT3, met or exceeded performance expectations when evaluated with proposed commercial herbicide application rates.

Key Points: 
  • 2023 field trial results have confirmed that rice herbicide tolerance (HT) traits, known as HT1 and HT3, met or exceeded performance expectations when evaluated with proposed commercial herbicide application rates.
  • Cibus expects to have field scale demonstrations of the HT rice traits in the US Mid-South in 2024 and expand to other geographies in 2025.
  • “This is an exciting development for both Cibus and the rice industry,” added Norm Sissons, Senior Vice President, Seed & Traits.
  • Meanwhile, Cibus expects the first field results of its PSR trait in WOSR in the United Kingdom later this year.

Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now Controlled by the World's 10 Largest Cord Blood Banking Operators - ResearchAndMarkets.com

Retrieved on: 
Monday, January 22, 2024
Health, Other Health, GCBC, Catalent, Stemcell Technologies, HSCT, Population growth, Cryopreservation, CBUS, Leukemia, Regenerative medicine, Cord blood, The Cooper Companies, Cerebral palsy, Spectrum, Research, Geography, UCB, LifeCell International, Registry, Hearing loss, Tissue, Cryo-Cell International, Cancer, GMP, ClinicalTrials.gov, Disorder, Acquisition, Sickle cell disease, Safety, Patient, MNC, NIH, Transplant, Certification, FDA, Amniotic fluid, Microsoft Exchange Server, Hematopoietic stem cell transplantation, Cell

There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.

Key Points: 
  • There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The vast majority of the global cord blood market is now controlled by the world's 10 largest cord blood banking operators.
  • It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis.